Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Inhibrx, Inc. INBX
$24.43
-$0.62 (-2.55%)
На 18:03, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
1154392952.00000000
-
week52high
34.72
-
week52low
7.67
-
Revenue
2178000
-
P/E TTM
-8
-
Beta
2.85820800
-
EPS
-4.23000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 10:59
Описание компании
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SMBC Nikko | Outperform | 25 авг 2022 г. | |
| Credit Suisse | Outperform | Outperform | 09 авг 2022 г. |
| SMBC Nikko | Outperform | 16 мар 2022 г. | |
| JMP Securities | Market Outperform | Market Outperform | 02 мар 2022 г. |
| Credit Suisse | Outperform | Outperform | 10 ноя 2021 г. |
| Evercore ISI Group | Outperform | Outperform | 05 окт 2022 г. |
| Credit Suisse | Outperform | Outperform | 08 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Eckelman Brendan P. | D | 2075553 | 1130 | 02 февр 2023 г. |
| Eckelman Brendan P. | D | 2076683 | 10120 | 02 февр 2023 г. |
| Eckelman Brendan P. | D | 2086803 | 693 | 01 февр 2023 г. |
| Eckelman Brendan P. | D | 2087496 | 14608 | 01 февр 2023 г. |
| Eckelman Brendan P. | D | 2102104 | 13449 | 01 февр 2023 г. |
| Lappe Mark | D | 2486252 | 63 | 24 янв 2023 г. |
| Lappe Mark | D | 2486315 | 4272 | 24 янв 2023 г. |
| Lappe Mark | D | 2490587 | 21665 | 23 янв 2023 г. |
| Kayyem Jon Faiz | D | 3224301 | 9500 | 23 янв 2023 г. |
| Eckelman Brendan P. | D | 2115553 | 3003 | 04 янв 2023 г. |
Новостная лента
Inhibrx Announces Participation in Upcoming Investor Conference
PRNewsWire
18 ноя 2022 г. в 16:05
SAN DIEGO , Nov. 18, 2022 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today announced it will be presenting at the following upcoming virtual investor conference: The Evercore ISI 5th Annual HealthCONx Conference Wednesday, November 30 th at 8:45 a.m. Pacific Time The investor conference presentation will be webcast live for at least 60 days following the event and will be accessible through a link on the investors section of Inhibrx's website at https://inhibrx.investorroom.com/events-and-presentations.
Inhibrx, Inc. (INBX) Reports Q3 Loss, Misses Revenue Estimates
Zacks Investment Research
07 ноя 2022 г. в 19:35
Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of 10.89% and 60.29%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Is Inhibrx (INBX) Stock Soaring 45% Today?
InvestorPlace
04 окт 2022 г. в 15:33
Following a rough outing throughout much of this year, biopharmaceutical firm Inhibrx (NASDAQ: INBX ) finally gave stakeholders reason to smile. Earlier today, the company announced it discussed with the Food and Drug Administration (FDA) matters associated with its key therapeutic INBRX-101.
Biotech Stock Soars on Potential FDA Fast-Track
Schaeffers Research
04 окт 2022 г. в 13:58
The shares of Inhibrix Inc (NASDAQ:INBX) are soaring today, up 41.1% at $28.48 at last glance, after the company alluded to potentially accelerated U.S. Food & Drug Administration (FDA) approval of its treatment for rare lung disease.
Inhibrx, Inc. (INBX) Reports Q2 Loss, Lags Revenue Estimates
Zacks Investment Research
08 авг 2022 г. в 21:04
Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -15.48% and 21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?